Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1363-1369

  Sadler, Matthew D ^a   Coffin, Carla S ^a   Lee, Samuel S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Chronic hepatitis B; Cirrhosis; Entecavir; Nucleot(s)ide analog; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; DECOMPENSATED LIVER CIRRHOSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LACTIC ACIDOSIS; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; REVIEW; SIDE EFFECT; STEADY STATE; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 84878845873     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.786701     Document Type: Review

References (44)

1. WHO Hepatitis B Fact Sheet [Internet]. 2012. Available from: http://www.who. int/mediacentre/factsheets/fs204/en/
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
3. Lok ASF, McMahon BJ, Chronic hepatitis B. Hepatology 2007;45:507-39
4. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
5. de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5
6. Chen C-J, Iloeje UH, Yang H-I. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007;11:797-816; viii
7. Iloeje UH, Yang H-I, Chen C-J. Natural history of chronic hepatitis B: What exactly has REVEAL revealed? Liver Int 2012;32:1333-41
8. Peng C-Y, Chien R-N, Liaw Y-F. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-50
9. Chang T-T, Liaw Y-F, Wu S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
10. Cho Y, Lee DH, Chung KH, et al. The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. Dig Dis Sci 2012. [Epub ahead of print]
11. Yip B, Chaung K, Wong CR, et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012;57:3011-16
12. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82
13. Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
14. Liaw Y-F, Sheen I-S, Lee C-M, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
15. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-83
16. Hsu Y-C, Mo L-R, Chang C-Y, et al. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther (Lond.) 2012;17:605-12
17. Hyun JJ, Seo YS, Yoon E, et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012;32:656-64
18. Koklu S, Tuna Y, Gulsen MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2012;11:88-94
19. Marcellin P, Buti M, Gane EJ, et al. Six years of treatment with tenofovir DF for chronic hepatitis b virus infection is and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2012;56(4 Suppl):374A-5A
20. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-2
21. Coffin CS, Fung SK, Ma M. Management of chronic hepatitis B: canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38
22. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61
23. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35:674-89
24. Zoutendijk R, Reijnders JGP, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2012. [Epub ahead of print]
25. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75
26. Chang T-T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
27. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
28. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
29. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3
30. Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8
31. Price PM, Banerjee R, Jeffrey AM, et al. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine. Hepatology 1992;16:8-12
32. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525-32
33. Baraclude Product Monograph. 2010
34. Yan J-H, Bifano M, Olsen S, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 2006;46:1250-8
35. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11
36. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
37. Lee GH, Aung MO, Dan YY, et al. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? J Med Virol 2013;85:26-33
38. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
39. Marcellin P, Chang T-T, Lim SGL, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
40. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
41. Woodward CLN, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-7
42. FDA Baraclude Prescribing Information
43. Peignoux MM, Lapalus M, Asselah T. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013
44. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-29